Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ Cell Stem Cellarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
Cell Stem Cell
Article
License: Elsevier Non-Commercial
Data sources: UnpayWall
image/svg+xml Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao Closed Access logo, derived from PLoS Open Access logo. This version with transparent background. http://commons.wikimedia.org/wiki/File:Closed_Access_logo_transparent.svg Jakob Voss, based on art designer at PLoS, modified by Wikipedia users Nina and Beao
Cell Stem Cell
Article . 2017 . Peer-reviewed
License: Elsevier Non-Commercial
Data sources: Crossref
https://pubmed.ncbi.nlm.nih.go...
Article . 2019
Data sources: Europe PubMed Central
 View all 2 versions
Claim

Looking Back: Disease Modeling

descriptionPublicationkeyboard_double_arrow_right Article 01 Jun 2017 English Publisher:Elsevier BVJournal:Cell Stem Cell, volume 20, page 756 (issn: 1934-5909, Copyright policy )

doi: 10.1016/j.stem.2017.05.006

pmid: 28575692

Looking Back: Disease Modeling

Abstract

Over the past decade, the growth of stem cell-based models of human disorders has contributed to novel drug discovery and precision medicine possibilities. For our tenth anniversary, we asked authors who cited a selection of our most popular papers in this area about how these studies influenced them.

Keywords

Oligodendrocyte Precursor Cells, Disease Models, Animal, Mice, Drug Discovery, Induced Pluripotent Stem Cells, Animals, Humans, Precision Medicine

  • BIP!
    Impact byBIP!
    selected citations
    These citations are derived from selected sources.
    This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 500
    popularity
    This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
    		 Top 1%
    influence
    This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
    		 Top 1%
    impulse
    This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
    		 Top 0.01%
Powered by OpenAIRE graph
Found an issue? Give us feedback
selected citations
These citations are derived from selected sources.
This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Citations provided by BIP!
popularity
This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.
BIP!Popularity provided by BIP!
influence
This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).
BIP!Influence provided by BIP!
impulse
This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.
BIP!Impulse provided by BIP!
500
Top 1%
Top 1%
Top 0.01%
hybrid